IMF Videos Search Content For Healthcare Professional (166) Healthcare Provider (165) Care Partner (128) Patient (128) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (261) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple Myeloma January 10, 2023 ASH MGUS and Risk of Chronic Kidney Disease: Results of the Population-Based iStopMM Study January 2, 2023 ASH Circulating Tumor Plasma Cells in the Screened iStopMM Smoldering Multiple Myeloma Cohort January 2, 2023 ASH Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM) December 27, 2022 ASH Clinical Impact of NGF in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess MRD in Newly Diagnosed Multiple Myeloma Pts Receiving Maintenance December 27, 2022 ASH Mezigdomide Combined with Dex in Relapsed/Refractory MM Pts: CC-92480-MM-001 Trial December 27, 2022 ASH Ultra-Sensitive Assessment of MRD in Peripheral Blood of Multiple Myeloma Patients Using Bloodflow December 26, 2022 ASH Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMM December 23, 2022 ASH Hypercalcemia in Individuals with MGUS: Results from the iStopMM Study December 23, 2022 ASH KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma December 23, 2022 ASH Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T-cell Therapy December 23, 2022 ASH Multiomics Profiling of MRD for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma December 22, 2022 ASH Load More
